Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Allocation: Randomized (Cohorts 1, 2 and Part B of 1c/1d), Non-Randomized (Cohorts 1b, and Part A of 1c/1d)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with histologically confirmed Grade IV malignant glioma
Previous treatment with radiotherapy and temozolomide (Cohorts 1, 1b and 2 only)
First recurrence of GBM (Cohorts 1, 1b and 2 only)
First diagnosis of GBM with resectable disease (Cohorts 1c Part A only)
First diagnosis of unmethylated MGMT GBM (Cohort 1d and Cohort 1c Part B only)
Karnofsky performance score of 70 or higher
You may not be if
More than 1 recurrence of GBM (Cohorts 1, 1b and 2 only)
Any recurrence of GBM (Cohorts 1c and 1d only)
Presence of extracranial metastatic or leptomeningeal disease
Active, known or suspected autoimmune disease
Clinically significant cardiovascular disease
Prior bevacizumab or other Vascular Endothelial Growth Factor (VEGF) or anti-angiogenic treatment (Cohort 2 only)
Clareo Health | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
